Современные клинические и молекулярно-генетические подходы к диагностике и лечению рака щитовидной железы
Диссертация
В тоже время наряду с прогрессом в молекулярно-биологических исследованиях РЩЖ, совершенствуются старые и разрабатываются новые клинические подходы. Высокоразрешающие и высокочувствительные методы лучевой и нелучевой диагностики РЩЖ также непрерывно улучшаются. Широкое внедрение метода УЗИ в практическое здравоохранение, наблюдаемое в течение последних двух десятилетий, привело к выявлению… Читать ещё >
Список литературы
- Автандилов Г. Г. Медицинская морфометрия . М.: Медицина, 1990. — С. 248−261.
- Балаболкин М.И., Клебанов Е. М., Креминская В. М. Фундаментальная и клиническая тироидология: Учеб. Пособие. М.: ОАО «Издательство «Медицина», 2007. — 816 е.: ил. С.685−718.
- Берштейн Л.М. Гормональный канцерогенез // Природа. 2000. — № 3. -С.22−7.
- Берштейн Л.М. Рак щитовидной железы: эпидемиология, эндокринология, факторы и механизмы канцерогенеза // Практ. онкол. -2007. № 8.-С. 1−8.
- Бочкарева Н.В., Коломиец Л. А., Кондакова И. В. и др. Ферменты метаболизма эстрогенов у больных раком эндометрия в сочетании с миомой матки // Медицина в Кузбассе: Спецвыпуск № 11−2004: Актуальные проблемы онкогинекологии. 2004. № 11, С. 10−14.
- Валдина Е.А. Заболевания щитовидной железы. С-Пт.: Питер, 2001. -397 с.
- Вестник Российского онкологического центра имени H.H. Блохина. Под ред. Давыдова М. И., Аксель Е. М. 2008. — том 19. с. 63−64.
- Волченко H. H. Цитологическая диагностика опухолей и опухолеподобных процессов щитовидной железы // Росс. Опкол. журн. 2004. № 6. С. 51−54.
- Гарбузов П.И., Дроздовский Б. Я., Родичев A.A. и др. Радиойодтерапия рака щитовидной железы // Практ. Онкол. 2007. — Т. 8, N 1.- С. 42 — 45.
- Горбань А. Н., Дунин-Барковский В. Л., Кирдин А. Н. и др. Нейроинформатика. Новосибирск: Наука, 1998. — 296 с.
- Гринева Е. Н., Малахова Т. В., Горюшкина Е. В. Роль тонкоигольной аспирационной биопсии в диагностике узловых образований щитовидной железы // Пробл. Эндокринол. 2005.- Т. 51. N. 1. — С. 10−15.
- Давыдов М.И., Аксель Е. М., Статистика злокачественных новообразований в России и странах СНГ в 2005 г. // Вест. РОНЦ им. H.H. Блохина РАМН 2009. — Т. 20, N З.(прил. 1) — С. 8 — 154.
- Дедов И. И. Свириденко Н.Ю. Иоддефицитные заболевания в Российской Федерации // Вестник Росс. Акад. Мед. Наук. 2001. — N 6.- С. 3−12.
- Дубский C.B. Современные подходы к лечению и реабилитации больных раком щитовидной железы: диссертация. доктора медицинских наук: 14.00.14, Томск. 2005. — 282 с.
- Ежов А., Чечеткин В. Нейронные сети в медицине // Открытые системы. -1997.-№ 4.-С. 34−37.
- Каллан Р. Основные концепции нейронных сетей. М.: Издательский дом «Вильяме», 2001. — 287 с.
- Любаев В.Л., Бржезовский В. Ж., Волкова Г. Ю. К вопросу о тактике лечения дифференцированных форм рака щитовидной железы // Практ.
- Онкол. 2007. — Т. 8. — N 1.- С. 26 — 28.205
- Маниатис Т., Фрич Э., Сэмбрук Д. Методы генной инженерии. Молекулярное клонирование: Пер. с англ. М.: Мир. — 1984. — С. 480.
- Мусабаева Л.И. Нейтронная терапия злокачественных новообразований / под ред. проф. Л. И. Мусабаевой, док. тех. наук В. А. Лисина. — Томск: Изд-во НТЛ, 2008. 288 с.
- Ольшанский В.О., Демидов В. П., Воронецкий И. Б. и др. Комбинированное и комплексное лечение больных со злокачественными опухолями // Руководство для врачей / Под редакцией В. И. Чиссова. М, 1989.-С. 180−193.
- Пачес А. И. Пропп Р.И. Рак щитовидной железы. Москва: Центр внедр.достиж. науки и техн. «Москва», 1995. — 372 с.
- Пачес А.И., Любаев В. Л., Шенталь В. В. и др. Современное состояние проблемы лечения рака щитовидной железы // Вопр. онкол. 1998. — Т. 44. — N 5.-С. 562−566.
- Пинский С.Б., Дворниченко В. В., Белобородов В. А. Опухоли щитовидной железы. Иркутск, 1999. — 320 с.
- Подвязников С.О. Рак щитовидной железы // Рус. Мед. Журнал 1998, т. 6, № 10, с. 658−664.
- Полоз Т.Л., Шкурупий В. А., Полоз В. В. Возможности использования искусственных многослойных нейронных сетей в дифференциальной диагностике опухолей // Омский научный вестник. 2007. — № 3 (61) — С. 55.
- Полоз Т.Л., Тарков М. С., Полоз В. В., Шкурупий В. А. Нейросетевая классификация цитологических изображений фолликулярных опухолейщитовидной железы // Системный анализ и управление в биомедицинских системах-.2006 Т.5. — № 3. — С.501−504.
- Полоз Т.Л., Шкурупий В. А., Полоз В. В. Дифференциально-диагностические возможности метода компьютерного анализа изображений фолликулярных опухолей щитовидной железы // Клиническая лабораторная диагностика. 2006. №. 3. — С. 42−44.
- Романчишен А.Ф., Колосюк В. А. Багатурия Т.О. Рак щитовидной железы- вопросы эпидемиологии, этиопатогенеза и лечения. СПб: Издательство «Welcome», 2003. — 256 с.
- Романчишен А.Ф., Колосюк В. А., Багатурия Т. О. Рак щитовидной железы- проблемы эпидемиологии, этиопатогенеза и лечения. Санкт-Петербург, — 2003.
- Тарков М.С., Полоз T.JI, Полоз В. В. Нейронная сеть для классификации изображений цитологических препаратов // Нейроинформатика: тез.докл. 9-й научн.-тех. конф., Москва -2007. С. 52.
- Тарков М.С., Полоз Т. Л., Полоз В. В. Нейросетевой анализатор изображений для цитологической диагностики фолликулярных опухолей щитовидной железы // Вестник Томского гос. Университета. Приложение 2006. — № 18 .- С. 185−188.
- Хорош О.Ю. Нормальная физиология гипоталамо-гипофизарно-тиреоидной системы и ее связь с другими эндокринными железами и нервной системой // Клиническая тиреоидология. 2005. — № 24.- С. 18.
- Цыб А.Ф., Паршин B.C., Нестайко Г. В. и др. Ультразвуковая диагностика заболеваний щитовидной железы. М.: Медицина, 1997. — 332 с.
- Чиссов В.И., Старинский В. В. Петрова Г. В. Злокачественные новообразования в России в 2003 г. (заболеваемость и смертность). -Москва: М., 2005. 228 с.
- Шапиро Н. А., Камнева Т. Н. Цитологическая диагностика заболеваний щитовидной железы. М., 2003. — С. 86.
- Шкурупий В.А., Полоз Т. Л. Цитоморфология фолликулярных опухолей щитовидной железы/Новосибирск, «Наука», 2009. 190 стр.
- Acharya S., Sarafoglou К., LaQuaglia M. et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence // Cancer. 2003. — Vol.97. — N 10. — P. 2397−2403.
- Adjei A., Weinshilboum R. Catecholestrogen sulfation: possible role in carcinogenesis // Biochem. Biophys. Res. Commun. 2002. Vol. 292. P. 402 408.
- Agate L., Lorusso L., Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors // J. Endocrinol. Invest. 2012. -Vol. 35. — P. 3−9.
- Ahmed M., Bin Yousef H., Greer W. et al. Hurthle cell neoplasm of the thyroid gland // ANZ J. Surg. 2008. — Vol. 78. — N 3.- P. 139−143.
- Akhtar M., Njar V., Wright J.N. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes // J. Steroid. Biochem. Mol. Biol. 1993. -V. 44. — P.375−87.
- Alberto Fernandez-Medarde and Eugenio Santos. Ras in Cancer and Developmental Diseases // Genes & Cancer.- 2002.- Vol. 2(3). P. 344−358
- Allocati N., Federici L., Masulli M., Di Ilio C. Glutathione transferases in bacteria // FEBS J. 2009. — Vol. 276. — N. 1. — P. 58−75
- Alonso O., Lago G., Mut F. et al. Thyroid imaging with Tc-99m MIBI in patients with solitary cold single nodules on pertechnetate imaging // Clin. Nucl. Med. 1996. — Vol. 21. — N 5.- P. 363−367.
- Alsanea O., Wada N., Ain K. et al. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series // Surgery. 2000. — Vol. 128. — N 6.- P. 1043−1050-discussion 1050−1041.
- Ambros V. The functions of animal microRNAs // Nature/ 2004. — Vol. 431. P. 350−355.
- American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules // Endocr. pract. 2007- Vol.12. — №.1. — P. 33−39
- Antonelli A., Fallahi P., Ferrari S.M. et al. Dedifferentiated thyroid cancer: a therapeutic challenge // Biomed. Pharmacother. 2008. — Vol. 62. — N 8.- P. 559−563.
- Atkinson J.C. Management of cervical lymph nodes in differentiated thyroid cancer // In: Mazzaferri E.L. et al. eds. Practical management of thyroid cancer Springer-Verlag: London. 2006. — 149−163 p.
- Bai Y., Kakudo K., Li Y. et al. Subclassification of non-solid-type papillary thyroid carcinoma identification of high-risk group in common type // Cancer. Sci. 2008. — Vol. 99. — N 10.- P. 1908−1915.
- Ball P., Knuppen R. Catecholoestrogens (2- and 4-hydroxyoetrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance.// Acta Endocrinol. Suppl. 1980. — Vol. 232. — P. 1−127.
- Baloch Z.W. LiVolsi V.A. Fine-needle aspiration of the thyroid: today and tomorrow // Best Pract. Res. Clin. Endocrinol. Metab. 2008. — Vol. 22. — N 6.-P. 929−939.
- Bardakci F, Arslan S, Bardakci S, Binatli AO, Budak M. Sulfotransferase 1 Al
- SULT1A1) polymorphism and susceptibility to primary brain tumors // J.
- Cancer Res. Clin. Oncol. 2008. — Vol. 134. — P.109−114
- Barbaro D., Simi U., Meucci G. et al. Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers -are they different diseases? // Clin. Endocrinol (Oxf). 2005. — Vol. 63. — N 5.-P. 577−581.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function // Cell. 2004. — Vol. 116. — P. 281−297.
- Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk R, Cuppen E. Phylogenetic shadowing and computational identification of human microRNA genes // Cell. 2005. — Vol. 120. — P. 21−24.
- Bilimoria K.Y., Bentrem D.J., Ko C.Y. et al. Extent of surgery affects survival for papillary thyroid cancer // Ann. Surg. 2007. — Vol. 246. — N 3.- P. 375−381- discussion 381−374.
- Bilimoria K.Y., Bentrem D.J., Linn J.G. et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States // Surgery. -2007. Vol. 142. — N 6.- P. 906−913- discussion 913 e901−902.
- Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, Winchester DP, Bentrem DJ. // Ann Surg. 2011. — Vol. 253. — P. 779−785.
- Bilimoria KY, Cohen ME, Merkow RP, Wang X, Bentrem DJ, Ingraham AM, Richards K, Hall BL, Ko CY. Comparison of outlier identification methods inhospital surgical quality improvement programs // J. Gastrointest. Surg. 2010. -Vol. 14.-P. 1600−1607.
- Boelaert K., Horacek J., Holder R.L. et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration // J. Clin. Endocrinol. Metab. 2006. — Vol. 91. — N 11.- P. 42 954 301.
- Bouville A., Likhtarev I.A., Kovgan L.N. et al. Radiation dosimetry for highly contaminated Belarusian, Russian and Ukrainian populations, and for less contaminated populations in Europe // Health Phys. 2007. — Vol. 93. — N 5.- P. 487−501.
- Brierley J.D. Tsang R.W. External beam radiation therapy for thyroid cancer // Endocrinol. Metab. Clin. North Am. 2008. — Vol. 37. — N 2.- P. 497−509, xi.
- Brose M.S., Troxel A.B., Redlinger M. et al. Effect of RAFV600E on response to sorafenib in advanced thyroid cancer patients// J. Clin. Oncol. -2009.-V. 27.-P. 6002.
- Bucci A., Shore-Freedman E., Gierlowski T. et al. Behavior of small thyroid cancers found by screening radiation-exposed individuals // J. Clin. Endocrinol. Metab. 2001. — Vol. 86. — N 8.- P. 3711−3716.
- Bufalo N.E., Leite J.L., Guilhen A.T. et al. Smoking and susceptibility to thyroid cancer: an inverse association with CYP1A1 allelic variants// Endocr. Relat. Cancer. 2006. — V. 13. — P. 1185−1189.
- Bullun, S. E., Lin, Z., et al. Regulation of Aromatase Expression in Estrogen-Responsive Breast and Uterine Disease: From Bench to Treatment // Pharmacological Rev. 2005. — Vol. 57. -N.3. — P. 359−383.
- Buscombe J., Hirji H. Witney-Smith C. Nuclear medicine in the management of thyroid disease // Expert Rev. Anticancer Ther. 2008. — Vol. 8. — N 9.- P. 1425−1431.
- Camera E., Picardo M. Analytical methods to investigate glutathione and related compounds in biological and pathological processes // J. Chromatography B 2002. — Vol. 781. — P. 181−206.
- Cantwell-Dorris E.R., O’Leary J.J., Sheils O.M. BRAFV600E: implications for carcinogenesis and molecular therapy// Mol. Cancer. Ther. 2011. — V. 10. -N. 3. — P.385−94.
- Cardis E., Kesminiene A., Ivanov V. et al. Risk of thyroid cancer after exposure to 1311 in childhood // J. Natl. Cancer. Inst. 2005. — Vol. 97. — N 10.-P. 724−732.
- Caron N.R., Tan Y.Y., Ogilvie J.B. et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary? // World J. Surg. 2006. — Vol. 30. — N 5.- P. 833−840.
- Carpi A., Mechanick J.I., Saussez S., Nicolini A. Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications // J. Cell Physiol. 2010. — Vol. 224. — P. 612−619.
- Castro M.R. Gharib H. Continuing controversies in the management of thyroid nodules // Ann. Intern. Med. 2005. — Vol. 142. — N 11.- P. 926−931.
- Chen Y.T., Kitabayashi N., Zhou X.K., Fahey T.J., Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma // Mod. Pathol. 2008. — Vol. 21(9). P. 1139−1146.
- Cheng S-Y., Leonard J. L., Davis P. J. Molecular Aspects of Thyroid Hormone Actions. // Endocr Rev. 2010. — Vol. 31(2). P. 139−170.
- Chiacchio S., Lorenzoni A., Boni G. et al. Anaplastic thyroid cancer: prevalence, diagnosis and treatment // Minerva Endocrinol. 2008. — Vol. 33. -N4.-P. 341−357.
- Chou C.K., Chen R.F., Chou F.F. et al. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF (V600E) mutation // Thyroid. 2010. — Vol. 20. — P. 489−494.
- Coecke S., Vanhaecke T., Foriers A. et al. Hormonal regulation of glutathione S-transferase expression in co-cultured adult rat hepatocytes// J. Endocrinol. -2000. V. 166. N. 2.-P. 363−371.
- Cohen E.G., Shaha A.R., Rinaldo A. et al. Medullary thyroid carcinoma // Acta Otolaryngol. 2004. — Vol. 124. — N 5.- P. 544−557.
- Cook M.B., Dawsey S.M., Freedman N.D. et al. Sex disparities in cancer incidence by period and age// Cancer Epidemiol. Biomarkers Prev. 2009. -V.18. — P. 1174−1182.
- Cookson M. S., Reuter V. E., Linkov I., Fair W. R. Glutathione S-transferase-pi (GST-pi) class expression by immunohistochemestry in benign and malignant prostate cancer // J. Urol.- 1997. Vol. 157. — N. 2. — P.673−678.
- Cooper D.S., Doherty G.M., Haugen B.R. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. -2006. Vol. 16. — N 2.- P. 109−142.
- Coughlin S. S. and Piper M. Genetic Polymorphisms and risk of breast cancer // J. Cancer Epidemiology, Biomarkers & Prevention. 1999. — Vol. 8. — P. 1023 — 1032.
- Coughtrie M.W., Johnston L.E. Interactions between dietary chemicals and human sulfotransferases-molecular mechanisms and clinical significance // Drug Metab. Dispos. 2001. — Vol. 29. — P. 522−528.
- Dal Maso L., Bosetti C., La Vecchia C. Franceschi S. Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors // Cancer Causes Control. 2009. — Vol. 20. — P. 75−86.
- Danielson P.B. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans // Curr. Drug Metab. 2002. — Vol. 3. — N. 6. — P. 561−597.
- Davidson H.C., Park B.J. Johnson J.T. Papillary thyroid cancer: controversies in the management of neck metastasis // Laryngoscope. 2008. — Vol. 118. — N. 12.-P. 2161−2165.
- Davies H., Bignell G.R., Cox C. et al. Mutations of the BRAF gene in human cancer// Nature. 2002. — Vol. 417. — P. 949−954.
- Davies L. Welch H.G. Epidemiology of head and neck cancer in the United States // Otolaryngol. Head Neck Surg. 2006. — Vol. 135. — N 3.- P. 451−457.
- Davies L. Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973−2002 // Jama. 2006. — Vol. 295. — N 18.- P. 2164−2167.
- De Falco M., Oliva G., Ragusa M. et al. Surgical treatment of differentiated thyroid carcinoma: a retrospective study // G. Chir. 2008. — Vol. 29. — N. 4.-P. 152−158.
- De Groot J.W., Links T.P., Sluiter W.J. et al. Locoregional control in patients with palpable medullary thyroid cancer: results of standardized compartment-oriented surgery // Head & Neck. 2007. — Vol. 29. — N 9.- P. 857−863.
- De Martino E., Pirola I., Gandossi E. et al. Thyroid nodular disease: an emerging problem // Minerva Endocrinol. 2008. — Vol. 33. — N. 1.- P. 15−25.
- DeGroot L.J. Kaplan E.L. Second operations for «completion» of thyroidectomy in treatment of differentiated thyroid cancer // Surgery. 1991. -Vol. 110. -N. 6.-P. 936−939.
- Delange F. Lecomte P. Iodine supplementation: benefits outweigh risks // Drug Saf. 2000. — Vol. 22. -N. 2.- P. 89−95.
- DeLellis R.A., Lloyd R.V., Heitz P.U. Eng C. WHO classification of tumors: pathology and genetics: tumors of endocirne organs. Lyon (France): IARC Press. — 2004. — 320 pp.
- Denison M.S., Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemical // Annu. Rev. Pharmacol. Toxicol. 2003. — Vol.43. — P. 309−334.
- Dotto J., Nose V. Familial thyroid carcinoma: a diagnostic algorithm // Adv Anat Pathol. 2008. — Vol. 15. — N 6.- P. 332−349.
- Dralle H. Machens A. Surgical approaches in thyroid cancer and lymph-node metastases // Best Pract. Res. Clin. Endocrinol. Metab. 2008. — Vol. 22. — N 6.- P. 971−987.
- Duffy B.J., Jr. Fitzgerald P.J. Thyroid cancer in childhood and adolescence- a report on 28 cases // Cancer. 1950. — Vol. 3. — N 6.- P. 1018−1032.
- Dzodic R., Markovic I., Inic M. et al. Sentinel lymph node biopsy may be used to support the decision to perform modified radical neck dissection in differentiated thyroid carcinoma // World J. Surg. 2006. — Vol. 30. — N 5.- P. 841−846.
- Egawa C., Miyoshi Y., Iwao K., Shiba E., Noguchi S. Quantative analysis of estrogen receptor -a and messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction // Oncology -2001.-Vol. 61 P. 293−298.
- Elaraj D.M. Clark O.H. Changing management in patients with papillary thyroid cancer // Curr. Treat. Options. Oncol. 2007. — Vol. 8. — N 4.- P. 305 313.
- Elisei R., Cosci B., Romei C., et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study // J. Clin. Endocrinol. Metab. 2008. — Vol. 93. — P. 682−687.
- Espinosa A .V., Porchia L., Ringel M. D. Targeting BRAF in thyroid cancer // Br. J. Cancer. 2007. — Vol. 96. — P. 16−20.
- Esquela-Kerscher A, Slack FJ. Oncomirs — MicroRNAs with a role in cancer// Nat. Rev. Cancer. 2006. — Vol. 6. — P. 259−269.
- Ezzat S., Sarti D.A., Cain D.R. Braunstein G.D. Thyroid incidentalomas. Prevalenceby palpation and ultrasonography // Arch. Intern. Med. 1994. -Vol. 154.-N. 16.- P.1838−1840.
- Fabian MR, Sonenberg N, Filipowicz W: Regulation of mRNA translation and stability by microRNAs// Annu. Rev. Biochem. 2010. — Vol.79. — P.351−379.
- Fagin J.A. Familial nonmedullary thyroid carcinoma—the case for genetic susceptibility // J. Clin. Endocrinol. Metab. 1997. — Vol.82. — P. 342−344.
- Falvo L., Giacomelli L., D’Andrea V. et al. Prognostic importance of sclerosing variant in papillary thyroid carcinoma // Am. Surg. 2006. — Vol. 72. — N 5.- P. 38−44.
- Farazi T.A., Spitzer J.I., Morozov P., Tuschl. T miRNAs in human cancer // J. Pathol. 2011. — Vol.223. — P. 102−115.
- Fierbracci P., Bonacci R., Gigliotti A. Breast cancer and thyroid autoimmunity // J. Endocr. Invest.-1996. Vol. 19. -N. 6. — P. 84−90.
- Fraker D.L. Radiation exposure and other factors that predipose to human thyroid neoplasia // Surg. Clin. North Am.- 1995.- Vol. 75. -N. 3.- P. 365−375.
- Franco R.L., Schenka N.G., Schenka A.A. et al. Glutathione S-transferase Pi expression in invasive breast cancer and its relation with the clinical outcome // J. BUON. 2012. — Vol. 17. — N. 2. — P. 259−264.
- Franklyn J.A., Maisonneuve P., Sheppard M. et al. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study//Lancet. 1999. — Vol. 353.-N. 9170.-P. 2111−2115.
- Frasca F., Nucera C., Pellegriti G. et al. BRAF (V600E) mutation and the biology of papillary thyroid cancer // Endoc. Rel. Cancer. 2008. — Vol.15. -P. 191−205.
- Frates M.C., Benson C.B., Charboneau J.W. et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement // Radiology. 2005. — Vol. 237. — N 3.- P. 794−800.
- Frattini M., Ferrario C., Bressan P. et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer // Oncogene. 2004. — Vol. 23. — N 44.- P. 7436−7440.
- Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs // Genome Res. 2009.- Vol.19. — P. 92 105.
- Fukahori M., Yoshida A., Hayashi H. et al. The association between RAS gene mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort // Thyroid. 2012. — Vol. 254. -P.712−723.
- Fukushima T., Suzuki S., Mashiko M. et al. BRAF mutations in papillary carcinomas of the thyroid // Oncogene. 2003. — Vol. 22. — N. 41.- P. 64 556 457.
- Furlan J.C. Rosen I.B. Prognostic relevance of previous exposure to ionizing radiation in well-differentiated thyroid cancer // Langenbecks Arch. Surg. -2004. Vol. 389. — N 3.- P. 198−203.
- Gandhi M., Evdokimova V., Nikiforov Y.E. Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma// Mol. Cell Endocrinol. 2010. — V. 321. — P. 36−43.
- Garcia-Rostan G, Costa AM, Pereira-Castro I. Mutation of the PIK3CA gene in anaplastic thyroid cancer // Cancer Res. 2005. — Vol. 65. — P. 199−207.
- Gate L., Majumdar R.S., Lunk A., Tew K.D. Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and Janus kinase/STAT pathways // J. Biol. Chem. 2004. -Vol. 279. -N.10.-P. 8608−8616.
- Gemsenjager E., Perren A., Seifert B. et al. Lymph node surgery in papillary thyroid carcinoma // J. Am. Coll. Surg. 2003. — Vol. 197. — N 2.- P. 182−190.
- Gharib H. Goellner J.R. Fine-needle aspiration biopsy of the thyroid: an appraisal // Ann. Intern. Med. 1993. — Vol. 118. — N 4.- P. 282−289.
- Gharib H. Papini E. Thyroid nodules: clinical importance, assessment, and treatment // Endocrinol. Metab. Clin. North Am. 2007. — Vol. 36. — N 3.- P. 707−735.
- Ghildiyal M., Zamore P.D. Small silencing RNAs: an expanding universe// Nat. Rev. Genet. 2009. — P.94−108.
- Gilfillan C.P. Review of the genetics of thyroid tumours: diagnostic and prognostic implications // ANZ J. Surg. 2010. — Vol. 80. — P. 33−40.
- Gimm O. Thyroid cancer // Cancer Lett. 2001. — Vol. 163. — N 2.- P. 143−56.221
- Goropoulos A., Karamoshos K., Christodoulou A. et al. Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma // World J. Surg. 2004. — Vol. 28. — N 12.- P. 1275−1281.
- Gosnell J.E. Clark O.H. Surgical approaches to thyroid tumors // Endocrinol. Metab. Clin. North Am. 2008. — Vol. 37. — N 2.- P. 437−455.
- Gow K.W., Lensing S., Hill D.A. et al. Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature // J. Pediatr. Surg. 2003. — Vol. 38. -N. 11.-P. 1574−1580.
- Green J.A., Robertson L.J., Clare A.H. Glutathione S-transferase expression in benign and malignant ovarian tumors // Br. J. Cancer. 1993. — Vol. 68. — № 2. — P. 235−239-
- Greenblatt D.Y., Elson D., Mack E. Chen H. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer // Asian J. Surg. -2007. Vol. 30. — N 2.- P. 108−112.
- Griggs W.S. Divgi C. Radioiodine imaging and treatment in thyroid disorders //Neuroimaging Clin. N. Am. 2008. — Vol. 18. — N 3.- P. 505−515.
- Grignon DJ, Abdel-Malak M, Mertens WC, Sakr WA, Shepherd RR. Glutathione S-transferase expression in renal cell carcinoma: a new marker of differentiation // Mod. Pathol. 1994. — Vol. 7. № 2. — P. 186−189.
- Grodski S., Brown T., Sidhu S. et al. Increasing incidence of thyroid cancer is due to increased pathologic detection // Surgery. 2008. — Vol. 144. — N 6.- P. 1038−1043- discussion 1043.
- Grodski S., Cornford L., Sywak M. et al. Routine level VI lymph node dissection for papillary thyroid cancer: surgical technique // ANZ J. Surg. -2007. Vol. 77. — N 4.- P. 203−208.
- Grubbs E.G., Rich T.A., Li G. et al. Recent advances in thyroid cancer // Curr. Probl.Surg. 2008. — Vol. 45. — N 3.- P. 156−250.
- Gulcelik M.A., Gulcelik N.E., Kuru B. et al. Prognostic factors determining survival in differentiated thyroid cancer // J. Surg. Oncol. 2007. — Vol. 96. — N 7.- P. 598−604.
- Gupta S., Ajise O., Dultz L. et al. Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities// Arch. Otolaryngol. Head Neck Surg. 2012. — V.138. N.3. -P.227−233.
- Gupta-Abramson V., Troxel A.B., Nellore A. et al. Phase II trial of sorafenib in advanced thyroid cancer// J. Clin. Oncol. 2008. -V. 26. — P.4714−4719.
- Hall P. Holm L.E. Cancer in iodine-131 exposed patients // J. Endocrinol. Invest. 1995. — Vol. 18. — N 2.- P. 147−149.
- Haq M. Harmer C. Thyroid cancer: an overview // Nucl. Med. Commun. -2004. Vol. 25. — N 9.- P. 861−867.
- Harach H.R. Williams E.D. Childhood thyroid cancer in England and Wales // Br J Cancer. 1995. — Vol. 72. — N 3.- P. 777−783.
- Harach H.R., Franssila K.O. Wasenius V.M. Occult papillary carcinoma of the thyroid. A «normal» finding in Finland. A systematic autopsy study // Cancer. -1985. -Vol. 56. N 3.- P. 531−538.
- Hashad D.I., Hashad M.M., Talaat I.M., Ibrahim M.A. Role of glutathione-S-transferase PI hypermethylation in molecular detection of prostate cancer// Genet. Test. Mol. Biomarkers. 2011. — Vol. 15. — N. 10. — P. 667−70.
- Hay I.D. Management of patients with low-risk papillary thyroid carcinoma // Endocr. Pract. 2007. — Vol. 13. — N 5.- P. 521−533.
- Hay I.D., Wass J. A eds. Clinical endocrine oncology Blackwell Publishing: Oxford. 2008. — 644 p.
- Haymart M.R., Glinberg S.L., Liu J. et al. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension // Clin. Endocrinol. (Oxf). 2008. — Vol.23. — P. 234−235.
- He H., Jazdzewski K., Li W., et al., The role of microRNA genes in papillary thyroid carcinoma // Proc Natl Acad Sci USA. 2005. — Vol. 102. — P. 1 907 519 080.
- He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J, de la Chapelle A. A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24 // Cancer Res. 2009. — Vol. 69(2). P. 625−631.
- He L., Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation // Nat. Rev. Genet. 2004. — Vol.5. — N.7. — P. 522−531.
- Heaney C.J. Wiseman G.A. Thyroid and parathyroid imaging. // In: Hay I.D. and Wass J.A. eds. Clinical endocrine oncology Blackwell Publishing: Oxford. 2008.- 116−123 p.
- Hegedus L. Clinical practice. The thyroid nodule // N. Engl. J. Med. 2004. -Vol. 351.-N 17.- P. 1764−1771.
- Henderson YC., Shellenberger T D:. Williams M D, El-Naggar A K. et al. High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma Clin // Cancer Res. 2009.- Vol. 15(2)P. 485 491.
- Hoang J.K., Lee W.K., Lee M. et al. US Features of thyroid malignancy: pearls and pitfalls // Radiographics. 2007. — Vol. 27. — N 3.- P. 847−860- discussion 861−845.
- Holm L.E. Cancer risks after diagnostic doses of 13II with special reference to thyroid cancer // Cancer Detect. Prev. 1991. — Vol. 15. — N 1.- P. 27−30.
- Holm L.E. Thyroid cancer after exposure to radioactive 1311 // Acta Oncol. -2006. Vol. 45. — N 8.- P. 1037−1040.
- Hubner R.A. Houlston R.S. Molecular advances in medullary thyroid cancer diagnostics // Clin. Chim. Acta. 2006. — Vol. 370. — N 1−2.- P. 2−8.
- Hundahl S.A., Fleming I.D., Fremgen A.M. Menck H.R. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985−1995 see commetns. // Cancer. 1998. — Vol. 83. — N 12.- P. 2638−2648.
- Hutvagner G., Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex// Science. 2002. — Vol.297. — N.5589. — P. 2056−2060.
- Iannuccilli J.D., Cronan J.J. Monchik J.M. Risk for malignancy of thyroid nodules as assessed by sonographic criteria: the need for biopsy // J. Ultrasound Med. 2004. — Vol. 23. — N 11.- P. 1455−1464.
- Inoe T., Ishida T. Sugio K., Maehara Y., Sugimachi K. Glutathione S-transferase-Pi is a powerful indicator in chemotherapy of human lung squamous- cell carcinoma // Respiration. 1995. — Vol. 62. № 4. — P. 223−227
- Inskip P.D. Thyroid cancer after radiotherapy for childhood cancer // Med. Pediatr. Oncol. 2001. — Vol. 36. — N 5.- P. 568−573.
- Ito Y. Miyauchi A. A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid // Nat. Clin. Pract. Endocrinol. Metab. 2007. -Vol. 3.-N3.- P. 240−248.
- Ito Y., Kakudo K., Hirokawa M. et al. Biological behavior and prognosis of familial papillary thyroid carcinoma // Surgery. 2009. — Vol. 145. — N 1.- P. 100−105.
- Jain S., Chen S., Chang K.C., Lin Y.J., et al. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma // PLoS One. 2012. — Vol. 7. — N. 4. — e35789.
- Jhaveri M.S., Stephens T.E., Morrow C.S. Role of posttranscriptional processes in the regulation of glutathione S-transferase PI gene expression in human breast cancer cells // Biochem. Biophys. Res. Commun. 1997. — Vol. 237. — N. 3. — P. 729−734.
- Jimenez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma // Endocrinol Metab. Clin. North. Am.- 2008.-Vol. 37. P. 481−496.
- Jimenez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma // Endocrinol. Metab. Clin. North. Am. 2008. — Vol. 37. — P. 481196.
- Kagava N., Hon H., Waterman M.R. et al Characterization of stable human aromatase expressed in E. coli // Steroids. 2004. — Vol. 69/ - № 2. — P. 235 243.
- Kamat A., Rajoria S., George A. et al. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways // Arch. Otolaryngol. Head Neck Surg. 2011. — Vol.137. — P. 11 461 153.
- Karakitsos P., Cochand-Priollet B., Pouliakis A., Guillausseau P.J., Ioakim-Liossi A. Learning vector quantizer in the investigation of thyroid lesions // Anal. Quan. t Cytol. Histol. 1999. — Vol. 21. — № 3. — P. 201−208.
- Katoh R., Sasaki J., Kurihara H. et al. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients // Cancer. 1992. — Vol. 70. — N 6.- P. 15 851 590.
- Kawajiri K., Nakachi K. Identification of genetically high risk individuals to lung cancer by DNA polymorphism of the cytochrome P450 1Al gene // FEBS Lett.-1990.-V. 263.-P. 131−3.
- Keatts E.L. Itano J. Medullary thyroid cancer and the impact of genetic testing // Clin. J. Oncol. Nurs. 2006. — Vol. 10. — N 5.- P. 571−575.
- Kebebew E, Weng J, Bauer J, Ranvier G et al. The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer Annals of Surgery Volume 246, Number 3, September 2007
- Kebebew E. Clark O.H. Locally advanced differentiated thyroid cancer // Surg. Oncol. 2003. — Vol. 12. — N 2.- P. 91−99.
- Keefe SM, Cohen MA, Brose MS Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications Clin // Cancer Res. 2010. — Vol. 16(3). — P. 778−783.
- Khoo M.L. Freeman J.L. Transcervical superior mediastinal lymphadenectomy in the management of papillary thyroid carcinoma // Head & Neck. 2003. -Vol. 25. -N l.-P. 10−14.
- Kim J.Y., Lee C.H., Kim S.Y. et al. Radiologic and pathologic findings of nonpalpable thyroid carcinomas detected by ultrasonography in a medical screening center // J. Ultrasound Med. 2008. — Vol. 27. — N 2.- P. 215−223.
- Kim K.H., Kang D.W., Kim S.H. et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population // Yonsei Med. J. 2004. -Vol. 45. -N 5.- P. 818−821.
- Kim M.K., Mandel S.H., Baloch Z. et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer // Arch. Otolaryngol. Head Neck Surg. 2004. — Vol. 130. — N 10.- P. 1214−1216.
- Kimura S. Thyroid-specific transcriptional factors and their roles in thyroid cancer. J Thyroid Res. 2011, article ID710213, 8 pages
- Kitajiri S., Hiraumi H., Hirose T. Hosaka N. The presence of large lymph node metastasis as a prognostic factor of papillary thyroid carcinoma // Auris Nasus Larynx.- 2003. Vol. 30. — N 2.- P. 169−174.
- Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, Zeiger MA, Kebebew E. Evaluation of Candidate Diagnostic MicroRNAs in Thyroid Fine-Needle Aspiration Biopsy Samples // Thyroid. 2012. Vol. 20. -P. 1−12.
- Kollermann J., Kempkensteffen C., Helpap B. et al. Impact of hormonal therapy on the detection of promoter hypermethylation of the detoxifying glutathione-S-transferase PI gene (GSTP1) in prostate cancer // BMC Urol. -2006.-Vol. 6.-P. 15−24.
- Kraimps J., Bouin L., Pineau M. et al. Familial papillary carcinoma of the thyroid // Surgery. 1995. — Vol. 118. — N. 6. — P. 1036−1040.
- Krutovskikh V. A. and Herceg Z. Oncogenic microRNAs (OncomiRs) as a new class of cancer biomarkers // Bioessays. 2010 — Vol. 32. P. 894−904.
- Kumagai A., Namba H., Saenko V.A. et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas // J. Clin. Endocrinol. Metab. -2004. Vol. 89. — N 9.- P. 4280−4284.
- Kuo S.F., Chao T.C., Hsueh C. et al. Prognosis and risk stratification in young papillary thyroid carcinoma patients // Endocr. J. 2008. — Vol. 55. — N 2.- P. 269−275.
- Lai H.W., Lee C.H., Chen J.Y. et al. Insular thyroid carcinoma: collective analysis of clinicohistologic prognostic factors and treatment effect with radioiodine or radiation therapy // J. Am. Coll. Surg. 2006. — Vol. 203. — N 5.-P. 715−722.
- Lam A.K. Lo C.Y. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution // Ann Surg Oncol. -2006. Vol. 13. — N 2.- P. 176−181.
- Lang B.H., Lo C.Y., Chan W.F. et al. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging // Ann. Surg. Oncol. 2007. — Vol. 14. — N 2.- P. 730−738.
- Lang B.H., Lo C.Y., Chan W.F. et al. Staging systems for papillary thyroid carcinoma: a review and comparison // Ann. Surg. 2007. — Vol. 245. — N 3.- P. 366−378.
- Lanzi C., Cassinelli G., Nicolini V. Zunino F. Targeting RET for thyroid cancer therapy // Biochem. Pharmacol. 2008. — Vol. 45. — P. 256−265.
- Lasabova Z, Tilandyova P, Kajo K, Zubor P et al. Hypermethylation of the GSTP1 promoter region in breast cancer is associated with prognostic clinicopathological parameters // Neoplasma. 2010. — Vol. 57. — P. 35−40.
- Lazarus J.H., Obuobie K. Thyroid disorders an update // Postgrad. Med. J. -2000. — Vol. 76. — P. 529−536.
- Lee A.J., Mills L.H., Kosh J.W., Conney A.H., Zhu B.T. NADPH-dependent metabolism of estrone by human liver microsomes. // J. Pharmacol. Exp. Ther. 2002. — Vol. 300. — P. 838−849.
- Lee A.J., Cai M.X., Thomas P.E., et al. Characterization of the oxidative metabolites of 17|3-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. // Endocrinology. 2003. — Vol. 144. — P. 3382−3398.
- Lee B.J., Wang S.G., Lee J.C. et al. Level lib lymph node metastasis in neck dissection for papillary thyroid carcinoma // Arch. Otolaryngol. Head Neck Surg. 2007. — Vol. 133. — N 10.- P. 1028−1030.
- Lee J., Sung T.Y., Nam K.H. et al. Is level lib lymph node dissection always necessary in Nib papillary thyroid carcinoma patients? // World J. Surg. -2008. Vol.32. — N 5.- P. 716−721.
- Lee J.I., Jang H.W., Kim S.W. et al. BRAF (V600E) mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas// Head Neck. 2012. — doi: 10.1002/hed.22 997.
- Lee S.H., Lee S.S., Jin S.M. et al. Predictive factors for central compartment lymphnode metastasis in thyroid papillary microcarcinoma // Laryngoscope. -2008. Vol. 118. — N 4.- P. 659−662.
- Lee Y.S., Kim S.W., Kim S.W. et al. Extent of routine central lymph node dissection with small papillary thyroid carcinoma // World J. Surg. 2007. -Vol. 31.-N10.-P. 1954−1959.
- Liehr J.G., Ricci M.J. 4-Hydroxylation of estrogens as marker of human mammary tumors. // Proc. Natl. Acad. Sci. USA. 1996. — Vol. 93. — P. 32 943 296.
- Lima J., Trovisco V., Soares P. et al. BRAF mutations are not a major event in post- Chernobyl childhood thyroid carcinomas // J. Clin. Endocrinol. Metab. -2004. Vol. 89. — N 9.- P. 4267−4271.
- Lin X., Nelson W.G. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells// Cancer Res. 2003. — Vol. 63. — N.2. — P.498−504.
- Lloyd R.V., Erickson L.A., Casey M.B. et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma // Am. J. Surg. Pathol. 2004. — Vol. 67. — P. 78−81.
- Lodish MB and Stratakis CA. RET oncogene in MEN2, MEN2B, MTC, and other forms of thyroid cancer: molecular genetics and therapeutic advances. // Expert Rev Anticancer Ther. 2008. Vol. 8(4). — P. 625−632.
- Loh K.C. Familial nonmedullary thyroid carcinoma: a meta-review of case series // Thyroid. 1997. — Vol. 7. -N 1.-P. 107−113.
- Lowery A.J., Miller N., MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer // Breast Cancer Res. 2009. — Vol. 11. — N. 3. — P. 27.
- Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent // J. Biol. Chem. 1951. — Vol. 193. — P. 265−275.
- Lu M., Zhang Q., Deng M., et al., An analysis of human microRNA and disease associations // PLoS ONE 2008. — Vol. 3. — P. 3420.
- Lundgren C.I., Delbridg L., Learoyd D. Robinson B. Surgical approach to medullary thyroid cancer // Arq. Bras. Endocrinol. Metabol. 2007. — Vol. 51. -N5.-P. 818−824.
- Luster M., Lassmann M., Freudenberg L.S. Reiners C. Thyroid cancer in childhood: management strategy, including dosimetry and long-term results // Hormones (Athens). 2007. — Vol. 6. — N 4.- P. 269−278.
- Machens A., Hofmann C., Hauptmann S. Dralle H. Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results // Eur. J. Endocrinol. 2007. — Vol. 157. — N 1.- P. 85−93.
- Machens A., Holzhausen H.J., Lautenschlager C. Dralle H. The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors // Langenbecks Arch. Surg. 2004. — Vol. 389. — N 4.- P. 278−282.
- Maffioli L., Steens J., Pauwels E. Bombardieri E. Applications of 99mTc-sestamibi in oncology // Tumori. 1996. — Vol. 82. — N 1.- P. 12−21.
- Malchoff C.D. Malchoff D.M. Familial nonmedullary thyroid carcinoma // Cancer Control. 2006. — Vol. 13. — N 2.- P. 106−110.
- Manole D., Schidknecht B., Gosnell B., Adams E., Derwahl M. Estrogen promotes growth of human thyroid tumor cells by different molecular mechanisms // J. Clin. Endocrin. Metab. 2001. — Vol. 86. — P. 1072−107.
- Marini F., Luzi E., Brandi M.L. MicroRNA Role in Thyroid Cancer Development // J Thyroid Res. 2011 — Vol. 12. — P. 234−239.
- Mathew C.G., Smith B.A., Thorpe K. et al. Deletion of genes on chromosome 1 in endocrine neoplasia // Nature. 1987. — Vol. 328. — N 6130.- P. 524−526.
- Mavis C.K., Morey Kinney S.R., Foster B.A., Karpf A.R. Expression level and DNA methylation status of glutathione-S-transferase genes in normal murine prostate and TRAMP tumors// Prostate. 2009. — Vol. 69. -N.12. — P. 1312−1324.
- Mazzaferri E., Harmer C., Mallik K., Kendall-Taylor P. Practical Management of Thyroid Cancer. A Multidisciplinary Appoach. London: Springer-Verlag 2006. — 445 p.
- Mazzaferri E.L. Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer // Am. J. Med. 1994. — Vol. 97. — N5.-P. 418−428.
- Mazzaferri E.L. Kloos R.T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer // J. Clin. Endocrinol. Metab. 2001. — Vol. 86. — N 4.- P. 1447−1463.
- Mazzaferri E.L. Management of low-risk differentiated thyroid cancer // Endocr. Pract. 2007. — Vol. 13. — N 5.- P. 498−512.
- Mazzaferri E.L. Sipos J. Should all patients with subcentimeter thyroid nodules undergo fine-needle aspiration biopsy and preoperative neck ultrasonography to define the extent of tumor invasion? // Thyroid. 2008. — Vol. 18. — N. 6.- P. 597−602.
- McCabe C.J. Moving towards the use of targeted therapies in thyroid cancer // Nat. Clin. Pract. Endocrinol. Metab. 2008. — Vol. 4. — N 11.- P. 604−605.
- McDougall I.R. Management of Thyroid Cancer and Related Nodular Disease. London: Springer-Verlag Ltd., 2006. — 397 p.
- Mendez W., Rodgers S.E., Lew J.I. et al. Role of surgeon-performed ultrasound in predicting malignancy in patients with indeterminate thyroid nodules // Ann. Surg. Oncol. 2008. — Vol. 15. — N 9.- P. 2487−2492.
- Miccoli P., Minuto M.N., Ugolini C. et al. Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer // Endocr. Relat. Cancer. -2007. Vol. 14. — N 4.- P. 1099−1105.
- Miccoli P., Minuto M.N., Ugolini C. et al. Intrathyroidal differentiated thyroid carcinoma: tumor size-based surgical concepts // World J Surg. 2007. — Vol. 31.-N5.-P. 888−894.
- Miccoli P., Minuto M.N., Ugolini C. et al. Papillary thyroid cancer: pathological parameters as prognostic factors in different classes of age // Otolaryngol. Head Neck Surg. 2008. — Vol. 138. — N 2. — P. 200−203.
- Mitchell I., Livingston E.H., Chang A.Y. et al. Trends in thyroid cancer demographics and surgical therapy in the United States // Surgery. 2007. -Vol. 142. — N 6.- P. 823−828- discussion 828 e821.
- Mitsiades C. S., Negri J., McMullan C. et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications// Mol. Cancer Therapeutics. 2007. -Vol. 6. -N. 3. — P. 1070−1078.
- Mitsutake N., Knauf J.A., Mitsutake S. et al. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells// Cancer Res. 2005. — Vol. .65.-P. 2465−2473.
- Moley J.F. Fialkowski E.A. Evidence-based approach to the management of sporadic medullary thyroid carcinoma // World J. Surg. 2007. — Vol. 31. — N 5.- P. 946−956.
- Moon W.J., Jung S.L., Lee J.H. et al. Benign and malignant thyroid nodules: US differentiation—multicenter retrospective study // Radiology. 2008. — Vol. 247. -N3. — P. 762−770.
- Morris L.F., Ragavendra N. Yeh M.W. Evidence-based assessment of the role of ultrasonography in the management of benign thyroid nodules // World J. Surg. 2008. — Vol. 32. — N 7.- P. 1253−1263.
- Namba H., Nakashima M., Hayashi T. et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers // J. Clin. Endocrinol. Metab. 2003. -Vol. 88. — N 9.- P. 4393−4397.
- Nataf B.M. Experimental research on thyroid cancer // Ann. Radiol.-1977. -Vol. 20.-N. 8. P.610−625.
- Neff R.L., Farrar W.B., Kloos R.T. Burman K.D. Anaplastic thyroid cancer // Endocrinol. Metab. Clin. North Am. 2008. — Vol. 37. — N 2 .- P. 525−538.
- Negishi M., Pedersen L.G., Petrotchenko E. et al. Structure and function of sulfotransferases // Arch. Biochem. Biophys. 2001. — Vol. 390. — N. 2. — P. 149−157.
- Ng E.K., Chong W.W., Jin H., et al., Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening // Gut 2009. — Vol. 58. — P. 1375−81.
- Nikiforova M.N., Ciampi R., Salvatore G. et al. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas // Cancer Lett. 2004. — Vol. 209. — N 1.- P. 1−6.
- Nobrega L.H., Paiva F.J., Nobrega M.L. et al. Predicting malignant involvement in a thyroid nodule: role of ultrasonography // Endocr. Pract. -2007. Vol. 13. -N. 3.- P.219−224.
- Noguchi S., Yamashita H., Uchino S. Watanabe S. Papillary microcarcinoma // World J Surg. 2008. — Vol. 32. — N 5.- P. 747−753.
- Nose V. Familial Non-Medullary Thyroid Carcinoma: An Update // Endocr. Pathol. 2008. — Vol. 19 -N. 4.- P. 226−240.
- Nose V. Familial thyroid cancer: a review // Mod Pathol. -2011. Suppl 2: S. -P. 19−33.
- Nucera C, Lawler J, Hodin R, Parangi S The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? // Oncotarget/ 2010. Vol. 1. P. 751 -756
- Nucera C., Goldfarb M., Hodin R., Parangi S. Role of B-Raf (V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf (V600E) // Biochim. Biophys. Acta. 2009. — Vol. 1795. — P. 152−161.
- Nucera C., Lawler J., Hodin R., Parangi S. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer? // Oncotarget. 2010. — Vol. 1. -P.751 -756.
- Okon k., Tomaszewska R., Nowakk k., Stachura J. // Anal. Cell Pathol. 2001. — Vol. 23. — № 3−4. — P. 129−136.
- Omerovic J, Laude AJ, Prior IA. Ras proteins: paradigms for compartmentalised and isoform-specific signaling // Cell Mol. Life Sci. 2007. -Vol. 64.-P. 2575−2589.
- Ort S. Goldenberg D. Management of regional metastases in well-differentiated thyroid cancer // Otolaryngol. Clin. North Am. 2008. — Vol. 41. -N6.-P. 1207−1218.
- Oskam I.M., Hoebers F., Balm A.J. et al. Neck management in medullary thyroid carcinoma // Eur. J. Surg. Oncol. 2008. — Vol. 34. — N 1.- P. 71−76.
- Pacini F., Schlumberger M., Dralle H. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium // Eur. J. Endocrinol. 2006. — Vol. 154. -N. 6.- P. 787−803.
- Pagano L., Klain M., Pulcrano M. et al. Follow-up of differentiated thyroid carcinoma // Minerva Endocrinol. 2004. — Vol. 29. — N 4.- P. 161−174.
- Palazzo F.F., Gosnell J., Savio R. et al. Lymphadenectomy for papillary thyroid cancer: changes in practice over four decades // Eur. J. Surg. Oncol. -2006. Vol. 32. -N. 3.- P. 340−344.
- Pallante P, Visone R, Croce CM, Fusco A. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas // Endocr. Relat. Cancer. 2010. — Vol. 17(1). P. 91−104.
- Parshkov E. Pathogenesis of radiation-induced thyroid cacner in children affected as a result of the Chernobyl accident // Int. J. Radiat. Med. 1999. -Vol. 3−4.-P. 67−75.
- Passler C., Scheuba C., Prager G. et al. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region // Endocr. Relat. Cancer. 2004. — Vol. 11. — N 1.- P. 131−139.
- Patel K.N. Shaha A.R. Locally advanced thyroid cancer // Curr. Opin. Otolaryngol. Head Neck Surg. 2005. — Vol. 13. — N 2.- P. 112−116.
- Pelizzo M.R., Boschin I.M., Toniato A. et al. Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients // Clin. Nucl. Med. -2007. Vol. 32. — N 6.- P. 440−444.
- Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A phase II study of gefitinib in patients with advanced thyroid cancer // Thyroid. 2008. — Vol. 18.-P. 317−323.
- Pereira J.A., Jimeno J., Miquel J. et al. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma // Surgery. 2005. -Vol. 138.-N 6.-P. 1095−1100, discussion 1100−1091.
- Peyssonnaux C. Eychene A. The Raf/MEK/ERK pathway: new concepts of activation // Biol. Cell. 2001. — Vol. 93. — N 1−2.- P. 53−62.
- Pillai, R. S. et al. Inhibition of translational initiation by let-7 microRNA in human cells. 2005. Science 309, 1573−1576.
- Pingpank J.F., Jr., Sasson A.R., Hanlon A.L. et al. Tumor above the spinal accessory nerve in papillary thyroid cancer that involves lateral neck nodes: a commonoccurrence // Arch. Otolaryngol. Head Neck Surg. 2002. — Vol. 128. -N11.-P. 1275−1278.
- Puzanov I., Burnett P., Flaherty K.T. Biological challenges of BRAF inhibitor therapy // Mol. Oncol. 2011. — Vol.5. -N.2. — P. 116−123.
- Qubain S.W., Nakano S., Baba M. et al. Distribution of lymph node micrometastasis in pNO well-differentiated thyroid carcinoma // Surgery. -2002. Vol. 131. — N 3.- P. 249−256.
- Rago T. Vitti P. Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules // Best Pract. Res. Clin. Endocrinol. Metab. 2008. — Vol. 22. -N6.-P. 913−928.
- Ramirez A.T., Gibelli B., Tradati N. et al. Surgical management of thyroid cancer // Expert Rev. Anticancer Ther. 2007. — Vol. 7. — N 9.- P. 1203−1214.
- Rand T.A., Petersen S., Du F., Wang X., Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation // CA Cancer J Clin 2005. — Vol. 123(4).-P. 621−629.
- Reading C.C., Charboneau J.W., Hay I.D. Sebo T.J. Sonography of thyroid nodules: a «classic pattern» diagnostic approach // Ultrasound Q. 2005. — Vol. 21.-N3.-P. 157−165.
- Richards M.L. Thyroid cancer genetics: multiple endocrine neoplasia type 2, nonmedullary familial thyroid cancer, and familial syndromes associated with thyroid cancer// Surg. Oncol. Clin. N. Am. 2009. — Vol. 18. — N 1.- P. 39−52.
- Rigoutsos I., Huynh T., Miranda K., et al., Short blocks from the noncoding parts of the human genome have instances within nearly all known genes and relate to biological processes // Proc Natl Acad Sci USA 2006. — Vol. 103. -P. 6605−6610.
- Ringel MD. Molecular markers of aggressiveness of thyroid cancer // Curr. Opin Endocrinol. Diabetes Obes. 2009. — Vol. 16(5). P. 361−366.
- Ritchie K.J., Henderson C.J., Wang XJ. et al. Glutathione transferase pi plays a critical role in the development of lung carcinogenesis following exposure to tobacco-related carcinogens and urethane // Cancer Res. 2007. — Vol.67. -N.19. -P.9248−9257.
- Robbins J. Factors altering thyroid hormone metabolism // Environ. Health Perspect. 1981. — Vol. 38. — P. 65−70.
- Robbins J. Schneider A.B. Thyroid cancer following exposure to radioactive iodine // Rev. Endocr. Metab. Disord. 2000. — Vol. 1. — N 3.- P. 197−203.
- Robbins K.T., dayman G., Levine P.A. et al. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the
- American Academy of Otolaryngology-Head and Neck Surgery // Arch. Otolaryngol. Head Neck Surg. 2002. — Vol. 128. — N 7.- P. 751−758.
- Roelants V. Beckers C. 99mTc-MIBI in differentiated thyroid carcinoma // J. Nucl. Med. 1999. — Vol. 40. — N 10. — P. 1769.
- Roh J.L. Park C.I. Sentinel lymph node biopsy as guidance for central neck dissection in patients with papillary thyroid carcinoma // Cancer. 2008. — Vol. 113.-N7.-P. 1527−1531.
- Roh J.L., Kim J.M. Park C.I. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis // Ann. Surg. Oncol. 2008. — Vol. 15. — N 9.- P. 2482−2486.
- Roh J.L., Kim J.M. Park C.I. Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection // Ann. Surg. Oncol. 2008. — Vol. 15. — N 4.- P. 1177−1182.
- Roh J.L., Yoon Y.H. Park C.I. Recurrent laryngeal nerve paralysis in patients with papillary thyroid carcinomas: evaluation and management of resulting vocal dysfunction // Am. J. Surg. 2008. — Vol. 34. — N 8.- P. 789−794
- Rojeski M.T. Gharib H. Nodular thyroid disease. Evaluation and management //N. Engl. J. Med. 1985. — Vol. 313. — N 7.- P. 428−436.
- Romagnoli S, Moretti S, Voce P, Puxeddu E. Targeted molecular therapies in thyroid carcinoma // Arq. Bras Endocrinol Metab. 2009. Vol. — 53(9). P. 1061−1073.
- Ron E. Ionizing radiation and cancer risk: evidence from epidemiology // Radiat. Res. 1998. — Vol. 150. — N 5 Suppl.- P. 30−41.
- Rubino C., Cailleux A.F., Abbas M. et al. Characteristics of follicular cell-derived thyroid carcinomas occurring after external radiation exposure: results of a case control study nested in a cohort // Thyroid. 2002. — Vol. 12. — N 4.-P. 299−304.
- Rushmore T. H., Pickett C. B. Glutathione S-transferases, structure, regulation and therapeutic implications // J. Biological. Chemistry. 1993. — Vol. 268. — P. 11 475−11 478-
- Sakorafas G.H., Giotakis J. Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective // Cancer Treat. Rev. 2005. — Vol. 31. — N. 6.- P. 423 438.
- Salajegheh A., Petcu E.B., Smith R.A. Lam A.K. Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists // Postgrad. Med. J. 2008. — Vol. 84. — N 988.- P. 78−82.
- Salgia R, Sherman S, Hong DS, et al. A phase I study of XL 184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroidcarcinoma (MTC) // J. Clin. Oncol. 2008. — Vol. 26. — P. 3522.
- Sanders E.M., Jr., LiVolsi V.A., Brierley J. et al. An evidence-based review of poorly differentiated thyroid cancer // World J. Surg. 2007. — Vol. 31. — N 5.-P. 934−945.
- Sarkar S.D. Benign thyroid disease: what is the role of nuclear medicine? // Semin. Nucl. Med. 2006. — Vol. 36. — N 3.- P. 185−193.
- Sathekge M.M., Mageza R.B., Muthuphei M.N. et al. Evaluation of thyroid nodules with technetium-99m MIBI and technetium-99m pertechnetate // Head & Neck. 2001. — Vol. 23. — N 4.- P. 305−310.
- Savio R., Gosnell J., Palazzo F.F. et al. The role of a more extensive surgical approach in the initial multimodality management of papillary thyroid cancer in children // J. Pediatr. Surg. 2005. — Vol. 40. — N 11.- P. 1696−1700.
- Schlumberger M. Pacini F. Thyroid tumors. Paris: Nucleon, 2003. — 355 p.
- Schlumberger M., Carlomagno F., Baudin E. et al. New therapeutic approaches to treat medullary thyroid carcinoma // Nat. Clin. Pract. Endocrinol. Metab. -2008.-Vol. 4.-N 1.-P. 22−32.
- Schneider A.B. Radiation-induced thyroid tumors // Endocrinol. Metab. Clin.
- North Am. 1990. — Vol. 19. — N 3.- P. 495−508.247
- Schneider A.B. Same D.H. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation // Nat. Clin. Pract. Endocrinol. Metab. -2005.-Vol. 1.-N2.- P. 82−91.
- Schneider A.B., Recant W., Pinsky S.M. et al. Radiation-induced thyroid carcinoma. Clinical course and results of therapy in 296 patients // Ann. Intern. Med. 1986. — Vol. 105. — N 3.- P. 405−412.
- Sclabas G.M., Staerkel G.A., Shapiro S.E. et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients // The Amer. J. of Surgery. 2003. Vol. 186.- 6. — P. 702−710.
- Sergieva S., Hadjieva T.- Doldurova M. et al. Nuclear medicine approaches in the monitoring of thyroid cancer patients // J. Buon. 2006. — Vol. 11. — N 4.- P. 511−518.
- Shah M.D., Hall F.T., Eski S.J. et al. Clinical course of thyroid carcinoma after neck dissection // Laryngoscope. 2003. — Vol. 113. — N 12.- P. 2102−2107.
- Shaha A. Selective surgical management of well-differentiated thyroid cancer // Ann. N. Y. Acad. Sci. 2008. — Vol. 1138. 58−64.
- Shaha A.R. Advances in the management of thyroid cancer // Int. J. Surg. -2005. Vol. 3. — N 3.- P. 213−220.
- Shaha A.R. Management of the neck in thyroid cancer // Otolaryngol. Clin. North. Am. 1998.-Vol. 31.-N 5.-P. 823−831.
- Shapiro N.A., Poloz T.L., Shkurupij V.A., Tarkov M.S., Poloz V.V., Demin A.V. Application of Artificial Neural Network for Classification of Thyroid Follicular Tumors // Anal. Quant. Cytol. Histol. 2007. — Vol. 29. — P.87−94.
- Sharma R., Mondai A., Shankar L.R. et al. Differentiation of malignant and benign solitary thyroid nodules using 30- and 120-minute tc-99m MIBI scans // Clin. Nucl. Med. 2004. — Vol. 29. — N 9.- P. 534−537.
- Shaver J.K., Tezelman S., Siperstein A.E. et al. Thyroid-stimulating hormone activates phospholipase C in normal and neoplastic thyroid tissue // Surgery.-1993. Vol.114. -N. 6. — P. 1064−1069.
- Sheehan D., Meade G. et al. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily // Biochem. J. 2001. — Vol. 360. — N. 1. — P. 116.
- Shen Li-Juan, Zang H. X., Zhang Z. J., Li J. Y, Chen M. Q., Yang W. B., Huang R. Detection of HBV, PCNA and GSTPl-lin hepatocellular carcinoma and chronic liver diseases // World J. Gastroenterol. 2003. — № 9. — P. 459 462.
- Sherman S.I. Thyroid carcinoma // Lancet. 2003. — Vol. 361. — N 9356.- P. 501−511.
- Sherman S.I., Angelos P., Ball D.W. et al. Thyroid carcinoma // J. Natl. Compr. Cane. Netw. 2007. — Vol. 5. — N 6.- P. 568−621.
- Sherman SI. Targeted therapy of thyroid cancer // Biochem Pharmacol. -2010. Vol. 80(5). P. 592−601.
- Simic T, Savic-Radojevic A, Pljesa-Ercegovac M et al. Glutathione S-transferases in kidney and urinary bladder tumors // J. Nat. Rev .Urol. 2009. --Vol. 6.-P. 281−289.
- Simpson, E.R., Davis, S.R. Minireview: Aromatase and the Regulation of Estrogen Biosynthesis — Some New Perspectives // Endocrinology 2001. -V. 142 -N. 11. -P. 4589—4594.
- Singal R., van Wert J., Bashambu M. Cytosine methylation represses glutathione S-transferase PI (GSTP1) gene expression in human prostate cancer cells // Cancer Res. 2001. Vol.61. — N.12. — P.4820−4826.
- Singer P.A. Evaluation and management of the solitary thyroid nodule // Otolaryngol. Clin. North Am. 1996. — Vol. 29. — N 4.- P. 577−591.
- Sipos J.A. Mazzaferri E.L. The therapeutic management of differentiated thyroid cancer // Expert Opin. Pharmacother. 2008. — Vol. 9. — N 15.- P. 2627−2637.
- Sippel R.S., Caron N.R. Clark O.H. An evidence-based approach to familial nonmedullary thyroid cancer: screening, clinical management, and follow-up // World J. Surg. 2007. — Vol. 31. — N 5.- P. 924−933.
- Siraj A.K., Ibrahim M., Al-Rasheed M. et al. Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population// BMC Med. Genet. 2008. — Vol. 5.-N. 9.-P. 61.
- Sobin L., Wittekind C, (eds.) TNM classification of malignant tumors, 6th edition. New York: Wiley-Liss., 2002. — 239 p.
- Sobol H., Narod S.A., Assouline D. Lenoir G.M. Genetic screening of endocrine tumour syndromes with DNA probes: the example of medullary thyroid carcinoma // Horm. Res. 1989. — Vol. 32. — N 1−3.- P. 34−40.
- Somerville H.M., Steinbeck K.S., Stevens G. et al. Thyroid neoplasia following irradiation in adolescent and young adult survivors of childhood cancer // Med. J. Aust. 2002. — Vol. 176. — N 12.- P. 584−587.
- Sosa J.A. Udelsman R. Total thyroidectomy for differentiated thyroid cancer // J.Surg. Oncol. 2006. — Vol. 94. — N 8.- P. 701−707.
- Sosa J.A., Bowman H.M., Tielsch J.M. et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy // Ann. Surg. 1998. — Vol. 228. — N 3.- P. 320−330.
- Stulak J.M., Grant C.S., Farley D.R. et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer // Arch. Surg. 2006. — Vol. 141. — N 5. — P. 489−494- discussion 494−486.
- Sturgeon C. Clark O.H. Familial nonmedullary thyroid cancer // Thyroid. -2005. Vol. 15. — N 6.- P. 588−593.
- Sturniolo G., Bonanno L., Gagliano E. et al. Surgical therapy of medullary thyroid carcinoma // Chir. Ital. 2007. — Vol. 59. — N 6.- P. 781−787.
- Sugitani I., Fujimoto Y., Yamada K. Yamamoto N. Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography // World J. Surg. 2008. — Vol. 32. — N 11.- P. 2494−2502.
- Sun Y., Zang Z., Xu X. et al. The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects // Breast Cancer Res. Treat. 2011. — Vol.125. — N. l -P. 215−219.
- Tallini G. Asa S.L. RET oncogene activation in papillary thyroid carcinoma // Adv.Anat. Pathol. 2001. — Vol. 8. — N 6.- P. 345−354.
- Tew K.D., Townsend D.M. Regulatory functions of glutathione S-transferase Pl-1 unrelated to detoxification // Drug. Metab. Rev. 2011. — Vol. 43. — N. 2. -P. 179−193.
- Tran N., McLean T., Zhang X., et al., MicroRNA expression profiles in head and neck cancer cell lines // Biochem Biophys Res Commun. 2007. — V.358. -P.12−17.
- Trovisco V., Vieira de Castro I., Soares P. et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma // J. Pathol. 2004. — Vol. 202. -N. 2.- P. 247−251.
- Tuttle R. M. Risk-adapted management of thyroid cancer // Endocrine Practice. 2008 — Vol. 14. -N. 6. — P. 764−774.
- Uchino S., Noguchi S., Kawamoto H. et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population // World J. Surg. 2002. — Vol. 26. — N 8.- P. 897−902.
- Udomsinprasert R., Pongjaroenkit S. et al. Identification, characterization and structure of a new Delta class glutathione transferase isoenzyme // Biochem. J. -2005.-Vol. 388.-N3.-P. 763−771.
- Wada N., Duh Q.Y., Sugino K. et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection // Ann. Surg. 2003. — Vol. 237.-N3.-P. 399−407.
- Wada N., Masudo K., Nakayama H. et al. Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age // Eur. J. Surg. Oncol. 2008. — Vol. 34. — N 2.- P. 202−207.
- Wan P.T., Garnett M.J., Roe S.M. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF // Cell. 2004. -Vol. 116.-P. 855−867.
- Wang S., Bian C., Yang Z., et al., miR-145 inhibits breast cancer cell growth through RTKN // Int J Oncol. 2009. — V.34. — P. 1461−1466.
- Wang T., Arifoglu P., Ronai Z., Tew K.D. Glutathione S-transferase Pl-1 (GSTP1−1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus // J. Biol. Chem. 2001. — Vol. 276. — P. 2429.
- Wang T.S., Roman S.A. Sosa J.A. Management of follicular tumors of the thyroid // Minerva Chir. 2007. — Vol. 62, — N 5.- P. 373−382.
- Vasieva O. The many faces of glutathione transferase pi // Curr. Mol. Med. -2011.-Vol. 11.-N.2.-P. 129−139.
- Vassilopoulou-Sellin R., Schultz P.N. Haynie T.P. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy // Cancer. 1996. — Vol. 78. — N 3.- P. 493−501.
- Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation // Science. 2007. — Vol. 21. — P. 318 (5858)
- Watkinson J.C. Management of cervical lymph nodes in differentiated thyroid cancer // In: Mazzaferri E.L. et al. eds. Practical management of thyroid cancer Springer-Verlag: London. 2006. — 149−163 p.
- Watkinson J.C., Franklyn J.A. Olliff J.F. Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer // Thyroid. 2006. — Vol. 16.-N 2 .-P. 187−194.
- Welker M.J. Orlov D. Thyroid nodules // Am. Fam. Physician. 2003. — Vol. 67.-N3.-P. 559−566.
- Wells SAJr. and Santoro M. Targeting the RET Pathway in Thyroid Cancer // Clin. Cancer Res. 2009. — Vol. 15. — P. 7119−7123.
- Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y, Stephens M, Pritchard JK. High resolution mapping of expression-QTLs yields insight into human gene regulation // PLoS Genet. 2008. — Vol. 4: el000214.
- White M.L., Gauger P.G. Doherty G.M. Central lymph node dissection in differentiated thyroid cancer // World J. Surg. 2007. — Vol. 31. — N 5.- P. 895 904.
- Vini L. Harmer C. Management of thyroid cancer // Lancet Oncol. 2002. -Vol. 3. — N. 7.-P. 407−414.
- Witt R.L. Initial surgical management of thyroid cancer // Surg. Oncol. Clin. N. Am. 2008. — Vol. 17. — N 1, — P. 71−91.
- Vriens MR, Weng J, Suh I, Huynh N, Guerrero MA, Shen WT, Duh QY, Clark OH, Kebebew E. MicroRNA expression profiling is a potential diagnostic toolfor thyroid cancer // Cancer. 2011. — doi: 10.1002/cncr.26 587. Epub ahead of print.
- Volinia, S. Calin GA, Liu CG, Ambs S, Cimmino A, et al. A microRNA expression signature of human solid tumors defines cancer gene targets // Proc. Natl Acad. Sci. US. 2006. — Vol. 103. — P. 2257−2261.
- Wu H., Zhu S., Mo Y.Y., Suppression of cell growth and invasion by miR-205 in breast cancer // Cell Res. 2009 — V.19(4). — P.439−48.
- Wu T., Giovannucci E., Welge J. et al. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis// Br. J. Cancer. 2011. — V. 105. — P. 65−73.
- Wu Y., Fan Y., Xue B. et al. Human glutathione S-transferase Pl-1 interacts with TRAF2 and regulates TRAF2-ASK1 signals// Oncogene. 2006. -Vol. 25.-N. 42. — P.5787−5800.
- Xia C., Hu J., Ketterer B., Taylor J. B. The organization of the human GSTP1 gene promoter and its response to retinoic acid and cellular redox status // Biochem. J. 1993. — Vol. 313. — P. 155−159.
- Xie X, Lu J, Kulbokas EJ, et al. Systematic discovery of regulatory motifs in human promoters and 3'-UTRs by comparison of several mammals // Nature. -2005. Vol. 434. — P. 338−445.
- Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications// Endocr. Rev. 2007. — Vol. 28. -P. 742−762.
- Xing M. BRAF mutation in thyroid cancer // Endocrine-Related Cancer. -2005. Vol. 12. — N. 2. — P. 245−262.
- Xing M., Clark D., Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer // J. Clin. Oncol. 2009. — Vol. 27. — N. 18. — P. 29 772 982.
- Xing M., Vasko V., Tallini G. et al. BRAF T1796A transversion mutation in various thyroid neoplasms // J. Clin. Endocrinol. Metab. 2004. — Vol. 89. — N. 3.-P. 1365−1368.
- Xiong Y, Zhang L, Holloway AK, Wu X, Su L, Kebebew E. MiR-886−3p regulates cell proliferation and migration, and is dysregulated in familial non-medullarythyroid cancer // PLoS One. 2011. — Vol. 6. — P. 55−57.
- Xu L., Doan P.C., Wei Q. et al. Association of BRCA1 functional single nucleotide polymorphisms with risk of differentiated thyroid carcinoma // Thyroid. -2012. Vol. 22.-N. 1.-P. 35−43.
- Xu X., Quiros R.M., Gattuso P. et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines // Cancer Res. -2003. Vol. 63. -N. 15.- P. 4561−4567.
- Yeung M.J. Serpell J.W. Management of the solitary thyroid nodule // Oncologist. 2008. — Vol. 13. -N. 2.- P. 105−112.
- Yip L, Kelly L, Shuai Y, Armstrong MJ, Nikiforov YE, Carty SE, Nikiforova MN. MicroRNA signature distinguishes the degree of aggressiveness ofpapillary thyroid carcinoma // Ann. Surg. Oncol. 2011. — Vol.18. — P. 20 352 041.
- Yoon H.Y., Kim S.K., Kim Y.W. et al. Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis // J. Biomol. Screen. 2012. — Vol. 17. — N. 7. — P. 987−992.
- Zaydfudim V., Feurer I.D., Griffin M.R. Phay J.E. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma // Surgery. 2008. — Vol. 144. — N 6.- P. 1070−1077- discussion 1077−1078.
- Zhang L., Xiao Y., Priddy R. Increase in placental glutathione S-transferase in human oral epinhelial dysplastic lesion and squamous cell carcinomas // J. Oral. Pathol. Med. 1994. — Vol. 23. — P. 75−79.
- Zivaljevic V., Paunovic I., Diklic A. et al. The incidence of familial nonmedullary thyroid cancer in a large case series // Acta Chir. Belg. 2008. -Vol. 108. -N3. — P. 328−333.